ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023 07:05 ET
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
September 27, 2023 07:07 ET
|
ZyVersa Therapeutics
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023 07:38 ET
|
ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
April 26, 2023 08:10 ET
|
Invea Therapeutics
GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
December 06, 2022 08:10 ET
|
Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
January 25, 2021 09:00 ET
|
Neuropathix, Inc.
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...
The Next Generation of Innovative Immunotherapy Agents, Inflammasome Inhibitors, Will Be Addressed in Panel Discussion on Monday, Feb. 17, 2020, at 10 a.m. EST
January 10, 2020 11:50 ET
|
Noble Capital Markets, Inc.
FORT LAUDERDALE, Fla., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Noble Capital Markets, Inc. (“Noble”) announced it has assembled a panel of scientists and experienced life science...